Spelling suggestions: "subject:"pharmacoeconomics"" "subject:"pharmacoeconomic""
1 |
The management of dyslipidemia in a private health care setting : a managed pharmaceutical care approach / Susan Mothekoa BopapeBopape, Susan Mothekoa January 2004 (has links)
The global anti-dyslipidemic market grew by 19% from 2000 to 2001, achieving sales of over
$21 billion (Smith, 2004: 2). This market is currently well sewed by a number of effective and
well-tolerated treatments. Lipid-lowering drugs are considered as the first choice drugs in control
of dyslipidemias and they are well tolerated by most patients. As with many drug therapies, there
should be a balance between the benefits of cholesterol lowering agents, increased medication
cost and the overall risk of adverse drug reactions. According to Ballesteros (2001: 514),
hypolipidemic drugs are consumed on a large scale and most consumers are elderly. This
warrants a study of expenditure incurred because of inadequate prescribing of these agents.
The general objective of this study was to determine the utilisation and cost of hypolipidemic
drugs in the private health care environment in South Africa. A quantitative retrospective drug
utilisation review was performed using a medicine claims database. Data for twenty-four
consecutive months (May 1, 2001 to April 30, 2003) were used to determine and compare the
utilisation patterns and cost of drugs associated with the management of dyslipidemia a year
before (1st May 2001 to 30 April 2002) and a year after (1st May 2002 to 30 April 2003) the
implementation of a medicine reference price system (MPL). Data analysis was done by
calculating the average value, the standard deviation, effect size, and cost-prevalence indices.
The results of this study revealed that hypolipidemic drugs constituted 2.70% (n = 21820911)
and 2.78% (n =27277825) of the total number of all medicine items for the first and the second
study years respectively. On the other hand, the total cost of all hypolipidemic drugs accounted
for 6.33% (n= R3 097 604 602) and 6.23 % (n= R 4 053 280 295) of the total cost of all
medicine items claimed during the first and the second study years respectively. The prevalence
of generic hypolipidemic drugs accounted for 0.89% (n=589036) and 4.88% (n=759675) of the
total number of hypolipidemic drugs claimed during the first and second study year respectively.
Innovator drugs, on the other hand, constituted 99.1 1% (n=589036) and 95.11% (n=759675) of
the total number of hypolipidemic drugs claimed during the first and second study years
respectively. It was found that R23 694.5 and R603 277.36 could have been saved for generic
bezafibrate and generic simvastatin respectively if they had been sold at ME'L prices. The total
cost of generic hypolipidemic drugs accounted for 0.60% and 2.94%. The total cost of innovator
hypolipidemic drugs accounted for 99.40% and 97.06% of the total cost of hypolipidemic drugs
claimed during the first (n=R 196 076 050) and second (n=R 252 919 285) study year
respectively. With respect to the prescribed daily dose, it was found that most prescriptions for
individual hypolipidemic drugs did not conform to the defined daily dose. It was, however,
found that most prescriptions whose prescribed daily dose was for one tablet once daily and
whose strength was similar to the defined daily dose conformed to the defined daily dose.
The conclusion is that there was an insignificant difference in both the prevalence and cost of
hypolipidemic drugs a year before and after the implementation of MPL. It was further
concluded that increased utilisation of generic hypolipidemic medicine items a year after the
implementation of the MPL, could have been brought about by the introduction of generic
simvastatin into the market as opposed to the implementation of the MPL. Recommendations for
further studies will be formulated. / Thesis (M.Pharm. (Pharmacy Practice))--North-West University, Potchefstroom Campus, 2005.
|
2 |
The usage of antidiabetic drugs : a managed care approach / Rianda SteynSteyn, Rianda January 2005 (has links)
"Diabetes mellitus" refers to a spectrum of conditions, which all present with hyperglycaemia as
a common medical finding. Diabetes was once thought of as a single disease, but according to
Setter et a/. (2000:378), it includes a heterogeneous group of disorders that are secondary to
various genetic predispositions and precipitating factors. Type 1 diabetes mellitus (DM)
accounts for 10 to 15% of all cases of diabetes mellitus and is clinically characterised by
hyperglycaemia and a propensity to diabetic keto-acidosis. Its control requires chronic insulin
treatment. Although it may occur at any age, it most commonly develops in childhood or
adolescence and is the predominant type of diabetes mellitus diagnosed before age 30 (Beers
& Berkow, 2004). Type 2 DM is usually the type diagnosed in patients older than 30 years of
age. It is also commonly associated with obesity (Berkow, 1992:1108).
The objective of this study was to review the usage and cost of antidiabetic drugs and to
determine the influence of the pricing regulations on the cost of these drugs. This research can
be classified as retrospective and quantitative. Data were obtained from a prescription claims
database, and the study population consisted of all the antidiabetic prescriptions for the year
1 January 2004 to 31 December 2004. The one-year period was divided into three study
periods, namely January to April, May to August and September to December.
Firstly diabetes mellitus was investigated in order to understand the disease and to determine
the prevalence and treatment thereof. It was found that diabetes mellitus is a heterogeneous
disorder acquired from both genetic and environmental factors and that education for the
general population, and in particular for the patients, is the key to preventing and controlling
diabetes and reducing the complications arising from it.
Secondly managed health care, pharmaco-economics and a drug utilisation review were
investigated in order to understand these concepts. The influence of the South African
Government on health care was discussed, including the new pricing regulations of medicine in
South Africa.
Thirdly, the utilisation patterns of antidiabetic drugs were reviewed, analysed and interpreted. It
was determined that the oral antidiabetic agents are relatively less expensive than the insulins
and that they are prescribed more frequently, and secondly that the biguanides presented
almost half (49.4%, n = 116 138) of all the oral antidiabetic agents. It was also determined that
the average cost of the oral antidiabetic drugs was between 21 .O% and 28.0% lower in 2004
than in 1996 - an indication that, despite inflation, the antidiabetic drugs were less expensive in
2004 than eight years ago in 1996. It was also calculated that the total cost savings in
antidiabetic medication could have been R1 448 682.26 if the lower price of antidiabetic agents
had been implemented during the period January to April. And finally it was also determined
that further substantial "cost savings" could have been possible if all the innovator antidiabetic
products had been substituted for less expensive generic antidiabetic products.
Abstract / Thesis (M.Pharm. (Pharmacy Practice))--North-West University, Potchefstroom Campus, 2006.
|
3 |
The management of dyslipidemia in a private health care setting : a managed pharmaceutical care approach / Susan Mothekoa BopapeBopape, Susan Mothekoa January 2004 (has links)
The global anti-dyslipidemic market grew by 19% from 2000 to 2001, achieving sales of over
$21 billion (Smith, 2004: 2). This market is currently well sewed by a number of effective and
well-tolerated treatments. Lipid-lowering drugs are considered as the first choice drugs in control
of dyslipidemias and they are well tolerated by most patients. As with many drug therapies, there
should be a balance between the benefits of cholesterol lowering agents, increased medication
cost and the overall risk of adverse drug reactions. According to Ballesteros (2001: 514),
hypolipidemic drugs are consumed on a large scale and most consumers are elderly. This
warrants a study of expenditure incurred because of inadequate prescribing of these agents.
The general objective of this study was to determine the utilisation and cost of hypolipidemic
drugs in the private health care environment in South Africa. A quantitative retrospective drug
utilisation review was performed using a medicine claims database. Data for twenty-four
consecutive months (May 1, 2001 to April 30, 2003) were used to determine and compare the
utilisation patterns and cost of drugs associated with the management of dyslipidemia a year
before (1st May 2001 to 30 April 2002) and a year after (1st May 2002 to 30 April 2003) the
implementation of a medicine reference price system (MPL). Data analysis was done by
calculating the average value, the standard deviation, effect size, and cost-prevalence indices.
The results of this study revealed that hypolipidemic drugs constituted 2.70% (n = 21820911)
and 2.78% (n =27277825) of the total number of all medicine items for the first and the second
study years respectively. On the other hand, the total cost of all hypolipidemic drugs accounted
for 6.33% (n= R3 097 604 602) and 6.23 % (n= R 4 053 280 295) of the total cost of all
medicine items claimed during the first and the second study years respectively. The prevalence
of generic hypolipidemic drugs accounted for 0.89% (n=589036) and 4.88% (n=759675) of the
total number of hypolipidemic drugs claimed during the first and second study year respectively.
Innovator drugs, on the other hand, constituted 99.1 1% (n=589036) and 95.11% (n=759675) of
the total number of hypolipidemic drugs claimed during the first and second study years
respectively. It was found that R23 694.5 and R603 277.36 could have been saved for generic
bezafibrate and generic simvastatin respectively if they had been sold at ME'L prices. The total
cost of generic hypolipidemic drugs accounted for 0.60% and 2.94%. The total cost of innovator
hypolipidemic drugs accounted for 99.40% and 97.06% of the total cost of hypolipidemic drugs
claimed during the first (n=R 196 076 050) and second (n=R 252 919 285) study year
respectively. With respect to the prescribed daily dose, it was found that most prescriptions for
individual hypolipidemic drugs did not conform to the defined daily dose. It was, however,
found that most prescriptions whose prescribed daily dose was for one tablet once daily and
whose strength was similar to the defined daily dose conformed to the defined daily dose.
The conclusion is that there was an insignificant difference in both the prevalence and cost of
hypolipidemic drugs a year before and after the implementation of MPL. It was further
concluded that increased utilisation of generic hypolipidemic medicine items a year after the
implementation of the MPL, could have been brought about by the introduction of generic
simvastatin into the market as opposed to the implementation of the MPL. Recommendations for
further studies will be formulated. / Thesis (M.Pharm. (Pharmacy Practice))--North-West University, Potchefstroom Campus, 2005.
|
4 |
The usage of antidiabetic drugs : a managed care approach / Rianda SteynSteyn, Rianda January 2005 (has links)
"Diabetes mellitus" refers to a spectrum of conditions, which all present with hyperglycaemia as
a common medical finding. Diabetes was once thought of as a single disease, but according to
Setter et a/. (2000:378), it includes a heterogeneous group of disorders that are secondary to
various genetic predispositions and precipitating factors. Type 1 diabetes mellitus (DM)
accounts for 10 to 15% of all cases of diabetes mellitus and is clinically characterised by
hyperglycaemia and a propensity to diabetic keto-acidosis. Its control requires chronic insulin
treatment. Although it may occur at any age, it most commonly develops in childhood or
adolescence and is the predominant type of diabetes mellitus diagnosed before age 30 (Beers
& Berkow, 2004). Type 2 DM is usually the type diagnosed in patients older than 30 years of
age. It is also commonly associated with obesity (Berkow, 1992:1108).
The objective of this study was to review the usage and cost of antidiabetic drugs and to
determine the influence of the pricing regulations on the cost of these drugs. This research can
be classified as retrospective and quantitative. Data were obtained from a prescription claims
database, and the study population consisted of all the antidiabetic prescriptions for the year
1 January 2004 to 31 December 2004. The one-year period was divided into three study
periods, namely January to April, May to August and September to December.
Firstly diabetes mellitus was investigated in order to understand the disease and to determine
the prevalence and treatment thereof. It was found that diabetes mellitus is a heterogeneous
disorder acquired from both genetic and environmental factors and that education for the
general population, and in particular for the patients, is the key to preventing and controlling
diabetes and reducing the complications arising from it.
Secondly managed health care, pharmaco-economics and a drug utilisation review were
investigated in order to understand these concepts. The influence of the South African
Government on health care was discussed, including the new pricing regulations of medicine in
South Africa.
Thirdly, the utilisation patterns of antidiabetic drugs were reviewed, analysed and interpreted. It
was determined that the oral antidiabetic agents are relatively less expensive than the insulins
and that they are prescribed more frequently, and secondly that the biguanides presented
almost half (49.4%, n = 116 138) of all the oral antidiabetic agents. It was also determined that
the average cost of the oral antidiabetic drugs was between 21 .O% and 28.0% lower in 2004
than in 1996 - an indication that, despite inflation, the antidiabetic drugs were less expensive in
2004 than eight years ago in 1996. It was also calculated that the total cost savings in
antidiabetic medication could have been R1 448 682.26 if the lower price of antidiabetic agents
had been implemented during the period January to April. And finally it was also determined
that further substantial "cost savings" could have been possible if all the innovator antidiabetic
products had been substituted for less expensive generic antidiabetic products.
Abstract / Thesis (M.Pharm. (Pharmacy Practice))--North-West University, Potchefstroom Campus, 2006.
|
5 |
A longitudinal study of the usage of acid reducing medicine using a medicine claims database / H.N. Janse van RensburgVan Rensburg, Hendrika Nicolien Janse January 2007 (has links)
Thesis (M.Pharm. (Pharmacy Practice))--North-West University, Potchefstroom Campus, 2008.
|
6 |
A longitudinal study of the usage of acid reducing medicine using a medicine claims database / Hendrika Nicolien Janse van RensburgJanse van Rensburg, Hendrika Nicolien January 2007 (has links)
Acid-related disorders are common, chronic conditions that have considerable impact on a patient's quality of life. In a study conducted by Majumdar et al. (2003:2411) the prevalence of chronic acid-related disorders was 2.3%. Acid-related disorders represent a major financial consideration with respect to the costs of drug prescribing (Whitaker, 1998:6). Health care cost increases each year. This leads to an increased interest in economic evaluation of health care and medical technologies (Anell & Svarvar, 2000:175). Health care providers no longer make treatment decisions independent of the consideration of the resultant cost. The treatment provided must not only provide value but the value must be documented to justify spending money. Economic evaluation research has emerged to offer guidance to policy makers, practitioners, health plans and institutions facing difficult treatment and coverage decisions (Ellis era/., 2002:271).
The main objectives of this study were to investigate the prescribing patterns and cost of acid reducing medicine with special reference to proton pump inhibitors and histamine-2 receptor antagonists in a section of the private health care sector of South Africa from 2001 to 2006. A longitudinal retrospective drug utilisation study was done on acid reducing medicine items claimed through a national medicine claims database. The five study years were 2001, 2002, 2004, 2005 and 2006. All the study years stretched from 1 January to 31 December.
It was determined that acid reducing medicine items prescribed decreased from 2.74% during 2001 to 2.50% during 2006 of all medicine items claimed. The same decreasing trend was observed regarding the cost of acid reducing medicine items. The cost percentage decreased from 4.89% (2001) to 3.72% (2006). However, the average cost per medicine item for the acid reducers increased by 5.35% from 2001 (R230.04 ± 176.29) to 2002 (R243.72 ± 184.18) and then decreased by 15.23% from 2002 to 2004. It again decreased with 15.05% from 2004
(R206.19 ± 179.42) to 2006 (R175.70 ± 172.55). The changes in the average cost of acid reducers were of no practical significance.
Proton pump inhibitors represented about half of the acid reducing medicine items prescribed and more than 70% of the total cost of acid reducing medicine items during the study years. The average cost of PPIs revealed a practical significant decrease (d > 0.8) from 2002 (R372.42 ± 156.62) to 2006 (R241.56 ± 177.21). H2RAs contributed between 15.00% and 18.26% of all acid reducing medicine items while contributing to between 9.68% and 16.85% of the total cost of all acid reducers.
The active ingredient most often prescribed was lansoprazole during 2001 and 2002, esomeprazole during 2004 and omeprazole during 2005 and 2006. Lanzor® 30mg was the acid reducer with the highest cost from 2001 to 2005, while Pariet® 20mg took the lead in 2006. Zantac® 150mg effervescent tablets were the H2RA, with the highest cost, during the five study years.
The percentage innovator items decreased by 4.50% from 2001 to 2002, increased by 1.01% from 2002 to 2004 and decreased again by 31.06% from 2004 to 2006. The slight increase in the percentage innovator medicine items claimed from 2002 to 2004 may be explained by the introduction of Nexiam® (esomeprazole) into the market in 2002. The total number of generic medicine items claimed contributed between 9.62% (n = R1 788 242.25) in 2001 and 30.75% (n = R3 196 163.34) in 2006 of the total cost of acid reducing medicine items.
The average cost per day of innovator medicine items was higher than the average cost per day of generic medicine items. This might be explained by a lower average cost for generic medicine items.
It was also determined that the prevalence of the two-drug regimens was the highest during the five study years. The Helicobacter pylori (H.pylori) eradication treatments, which included different antibiotics, increased from 2.72% in 2001 to 5.05% in 2006.
The PDD for most of the active ingredients of H2RAs and PPIs remained stable during the study years. However, it appears that the PDDs, of the PPIs, active ingredients were more constant than the PDDs, or the H2RAs, active ingredients. The median of the different PPI active ingredients was reasonably more constant than the median of the different H2RA active ingredients. Thus the changes between the PPIs' and H2RAs' active ingredients might be explained by the variation in the median (the number of days the relevant medicine item was claimed for).
It is then also recommended that the aspects of generic substitution as well as the usage of H2RAs as prescribed vs. self medication should be further investigated to increase possible cost savings. / Thesis (M.Pharm. (Pharmacy Practice))--North-West University, Potchefstroom Campus, 2008.
|
7 |
A longitudinal study of the usage of acid reducing medicine using a medicine claims database / Hendrika Nicolien Janse van RensburgJanse van Rensburg, Hendrika Nicolien January 2007 (has links)
Acid-related disorders are common, chronic conditions that have considerable impact on a patient's quality of life. In a study conducted by Majumdar et al. (2003:2411) the prevalence of chronic acid-related disorders was 2.3%. Acid-related disorders represent a major financial consideration with respect to the costs of drug prescribing (Whitaker, 1998:6). Health care cost increases each year. This leads to an increased interest in economic evaluation of health care and medical technologies (Anell & Svarvar, 2000:175). Health care providers no longer make treatment decisions independent of the consideration of the resultant cost. The treatment provided must not only provide value but the value must be documented to justify spending money. Economic evaluation research has emerged to offer guidance to policy makers, practitioners, health plans and institutions facing difficult treatment and coverage decisions (Ellis era/., 2002:271).
The main objectives of this study were to investigate the prescribing patterns and cost of acid reducing medicine with special reference to proton pump inhibitors and histamine-2 receptor antagonists in a section of the private health care sector of South Africa from 2001 to 2006. A longitudinal retrospective drug utilisation study was done on acid reducing medicine items claimed through a national medicine claims database. The five study years were 2001, 2002, 2004, 2005 and 2006. All the study years stretched from 1 January to 31 December.
It was determined that acid reducing medicine items prescribed decreased from 2.74% during 2001 to 2.50% during 2006 of all medicine items claimed. The same decreasing trend was observed regarding the cost of acid reducing medicine items. The cost percentage decreased from 4.89% (2001) to 3.72% (2006). However, the average cost per medicine item for the acid reducers increased by 5.35% from 2001 (R230.04 ± 176.29) to 2002 (R243.72 ± 184.18) and then decreased by 15.23% from 2002 to 2004. It again decreased with 15.05% from 2004
(R206.19 ± 179.42) to 2006 (R175.70 ± 172.55). The changes in the average cost of acid reducers were of no practical significance.
Proton pump inhibitors represented about half of the acid reducing medicine items prescribed and more than 70% of the total cost of acid reducing medicine items during the study years. The average cost of PPIs revealed a practical significant decrease (d > 0.8) from 2002 (R372.42 ± 156.62) to 2006 (R241.56 ± 177.21). H2RAs contributed between 15.00% and 18.26% of all acid reducing medicine items while contributing to between 9.68% and 16.85% of the total cost of all acid reducers.
The active ingredient most often prescribed was lansoprazole during 2001 and 2002, esomeprazole during 2004 and omeprazole during 2005 and 2006. Lanzor® 30mg was the acid reducer with the highest cost from 2001 to 2005, while Pariet® 20mg took the lead in 2006. Zantac® 150mg effervescent tablets were the H2RA, with the highest cost, during the five study years.
The percentage innovator items decreased by 4.50% from 2001 to 2002, increased by 1.01% from 2002 to 2004 and decreased again by 31.06% from 2004 to 2006. The slight increase in the percentage innovator medicine items claimed from 2002 to 2004 may be explained by the introduction of Nexiam® (esomeprazole) into the market in 2002. The total number of generic medicine items claimed contributed between 9.62% (n = R1 788 242.25) in 2001 and 30.75% (n = R3 196 163.34) in 2006 of the total cost of acid reducing medicine items.
The average cost per day of innovator medicine items was higher than the average cost per day of generic medicine items. This might be explained by a lower average cost for generic medicine items.
It was also determined that the prevalence of the two-drug regimens was the highest during the five study years. The Helicobacter pylori (H.pylori) eradication treatments, which included different antibiotics, increased from 2.72% in 2001 to 5.05% in 2006.
The PDD for most of the active ingredients of H2RAs and PPIs remained stable during the study years. However, it appears that the PDDs, of the PPIs, active ingredients were more constant than the PDDs, or the H2RAs, active ingredients. The median of the different PPI active ingredients was reasonably more constant than the median of the different H2RA active ingredients. Thus the changes between the PPIs' and H2RAs' active ingredients might be explained by the variation in the median (the number of days the relevant medicine item was claimed for).
It is then also recommended that the aspects of generic substitution as well as the usage of H2RAs as prescribed vs. self medication should be further investigated to increase possible cost savings. / Thesis (M.Pharm. (Pharmacy Practice))--North-West University, Potchefstroom Campus, 2008.
|
Page generated in 0.0776 seconds